Healthcare Providers and Services
Company Overview of Castle Biosciences Incorporated
Castle Biosciences Incorporated develops and commercializes diagnostic and prognostic tests for cancers. It offers DecisionDx-Melanoma, a gene expression profile test to identify stage I and II patients at high risk of metastasis based on biological information from 31 genes within their tumor tissue; DecisionDx-UM test to measure the activity or gene expression of a set of 15 genes within an ocular melanoma tumor to identify the likelihood of metastasis; and DecisionDx-EC test, which analyzes the localization of three protein biomarkers in a patient’s tumor to classify the cancer as either responsive to or resistant to pre-surgical chemoradiotherapy. The company also provides DecisionDx-Mes...
820 South Friendswood Drive
Friendswood, TX 77546
Founded in 2007
Key Executives for Castle Biosciences Incorporated
Founder, Chief Executive Officer, President and Director
Vice President of Operations
Director of Reimbursement
Executive Director of Medical Affairs
Compensation as of Fiscal Year 2015.
Castle Biosciences Incorporated Key Developments
Castle Biosciences, Inc. Announces Appointment of Bonnie H. Anderson to Board of Directors
Jun 29 15
Castle Biosciences Inc. announced the appointment of Bonnie H. Anderson to its Board of Directors. Ms. Anderson is the cofounder of Veracyte, where she serves as president and chief executive officer. Ms. Anderson’s career spans nearly 30 years in the diagnostics and life sciences markets. She cofounded Veracyte in 2008, spearheaded its successful initial public offering in 2013 and has led its commercialization efforts to date. Prior to Veracyte, Ms. Anderson provided strategic consulting services to venture capital firms and early-stage businesses following 18 years in various leadership roles at Beckman Coulter.
Castle Biosciences Announces National Payer Agreements with MultiPlan, Inc., FedMed, Inc. and Preferred Medical Claim Solutions
Jun 15 15
Castle Biosciences Inc. announced the company has secured payer contracts with MultiPlan Inc., FedMed Inc. and Preferred Medical Claim Solutions, LLC to provide coverage of its DecisionDx™ assays.
Castle Biosciences Incorporated Announces Board Changes
May 28 15
Castle Biosciences Incorporated appointed Patrick Hall, D.Ph., to the newly created role of Executive Director, Medical Affairs and announced the promotion of Robert W. Cook, Ph.D. Dr. Hall will oversee the development of Medical Affairs strategies and programs at Castle Biosciences. He joins the company with 27 years of industry experience in various roles in molecular diagnostics, bio-oncology, pharmaceutical sales and operations. Dr. Hall spent more than 11 years at Genomic Health Inc., most recently as Director of Genomic Science Liaisons, where he oversaw the medical affairs activities of its breast, colon and prostate cancer assays. In addition to this appointment, the Company announced the promotion of Robert W. Cook, Ph.D., who has served as Senior Scientist since 2011, to the newly created position of Executive Director, Research and Development.
Similar Private Companies By Industry
Recent Private Companies Transactions
July 27, 2015
August 11, 2014